Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder

References

• The National Institute of Mental Health. Schizophrenia. Health Educ. - Stat. 2016. Available at: https://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtml. [Last accessed 14 February 2017]
   Google Scholar
• The National Institute of Mental Health. Bipolar Disorder among Adults. Health Educ. - Stat. 2016. Available at: https://www.nimh.nih.gov/health/statistics/prevalence/bipolar-disorder-among-adults.shtml. [Last accessed 14 February 2017]
   Google Scholar
• Fischer BA, Buchanan RW. Schizophrenia in adults: clinical manifestations, course, assessment, and diagnosis. UpToDate. 2017. Available at: http://www.uptodate.com/contents/schizophrenia-in-adults-clinical-manifestations-course-assessment-and-diagnosis [Last accessed 9 June 2017]
   Google Scholar
• Stovall J. Bipolar disorder in adults: epidemiology and pathogenesis. UpToDate. 2016. Available at: https://www.uptodate.com/contents/bipolar%C2%ADdisorder%C2%ADin%C2%ADadults%C2%ADepidemiology%C2%ADand%C2%ADpathogenesis/print?source=search_result&search=bipolar%20stovall&select%E2%80%A6. [Last accessed 24 February 2017]
   Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization, 2003. Available at: http://books.google.com/books?hl=en&lr=&id=kcYUTH8rPiwC&oi=fnd&pg=PR5&dq=%22VI+%E2%80%93+How+can+improved+adherence+be+translated+into%22+%22XIII+%E2%80%93%22+%22III+%E2%80%93+Disease-specific%22+%22VIII+%E2%80%93+Cancer+(palliative%22+%22XI+%E2%80%93%22+%22X+%E2%80%93%22+%22VII+%E2%80%93%22+%22XII+%E2%80%93%22+&ots=tz5Kir5cv_&sig=c5FxwOS1GP1PLX8P5yKo_CJzhyA [Last accessed 5 March 2013]
   Google Scholar
• Haddad P, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62
   PubMedGoogle Scholar
• Lafeuille M-H, Frois C, Cloutier M, et al. Factors associated with adherence to the HEDIS quality measure in Medicaid patients with schizophrenia. Am Health Drug Benefits 2016;9:399-410
   PubMed Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 2017;11:449-68
   PubMed Web of Science ®Google Scholar
• Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs 2017;31:99-110
   PubMed Web of Science ®Google Scholar
• Yang J, Ko Y-H, Paik J-W, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res 2012;134:226-31
   PubMed Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 2016;36:355-71
   PubMed Web of Science ®Google Scholar
• El-Mallakh P, Findlay J. Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatr Dis Treat 2015;11:1077-90
   PubMed Web of Science ®Google Scholar
• De las Cuevas C, de Leon J, Peñate W, et al. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence 2017;11:681-90
   PubMed Web of Science ®Google Scholar
• Potkin S, Bera R, Zubek D, et al. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013;13:261
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-52
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Grunze H, Leucht S, et al. Long-acting injection antipsychotic medications in the management of schizophrenia. Evid-Based Psychiatr Care 2015;1:27-36
   Google Scholar
• Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ 2015;18:357-65
   PubMed Web of Science ®Google Scholar
• Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence 2017;11:619-29
   PubMed Web of Science ®Google Scholar
• Biagi E, Capuzzi E, Colmegna F, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther 2017;34:1036-48
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Laliberté-Auger F, Lefebvre P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 2013;13:221
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry 2017;17:207
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Wolfgang Fleischhacker W. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry 2017;4:117-26
   PubMedGoogle Scholar
• Bergeson JG, Kalsekar I, Jing Y, et al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits 2012;5:379-86
   PubMedGoogle Scholar
• Wu C-S, Hsieh MH, Tang C-H, et al. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. J Affect Disord 2016;197:189-95
   PubMed Web of Science ®Google Scholar
• Chou YH, Chu P-C, Wu S-W, et al. A systemic review and experts’ consensus for long-acting injectable antipsychotics in bipolar disorder. Clin Psychopharmacol Neurosci 2015;13:121-8
   PubMed Web of Science ®Google Scholar
• Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 2012;26:403-20
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014;4:198-219
   PubMedGoogle Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013;13:340
   PubMed Web of Science ®Google Scholar
• Jarema M, Wichniak A, Dudek D, et al. Practical guidelines for the use of long-acting injectable second-generation antipsychotics. Psychiatr Pol 2015;49:225-41
   PubMed Web of Science ®Google Scholar
• Malla A, Tibbo P, Chu P, et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry Rev Can Psychiatr 2015;58:30-5S
   Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry 2016;77:1-24
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: prevention and management. National Institute for Health and Care Excellence, 2014. Available at: https://www.nice.org.uk/guidance/cg178/resources/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133 [Last accessed 18 August 2017]
   Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006;36:1535
   PubMed Web of Science ®Google Scholar
• Khaykin E, Eaton W, Ford D, et al. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv 2010;61:830-4
   PubMed Web of Science ®Google Scholar
• Nau D. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. Springfield, VA: Pharmacy Quality Alliance, 2012
   Google Scholar
• Campagna EJ, Muser E, Parks J, et al. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Manag Care Spec Pharm 2014;20:756-66
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. HCUP Chronic Condition Indicator. HCUP, 2015. Available at: www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. [Last accessed 21 February 2017]
   Google Scholar
• Brnabic AJM, Kelin K, Ascher-Svanum H, et al. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study: medication discontinuation in outpatients with schizophrenia. Int J Clin Pract 2011;65:945-53
   PubMed Web of Science ®Google Scholar
• Zhu B, Ascher-Svanum H, Shi L, et al. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv Wash DC 2008;59:315-17
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013;74:568-75
   PubMed Web of Science ®Google Scholar
• Pesa JA, Muser E, Montejano LB, et al. Costs and resource utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs – Real World Outcomes 2015;2:377-385
   PubMedGoogle Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
   PubMed Web of Science ®Google Scholar
• Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn 2012;8:50-61
   PubMed Web of Science ®Google Scholar
• Kirschner M, Theodoridou A, Fusar-Poli P, et al. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 2013;3:89-99
   PubMedGoogle Scholar